Phase 1 trial finds triple monoclonal antibody combination safe and effective for HIV-1 prevention

This phase 1, multicentre, randomised, open-label trial (HVTN 140/HPTN 101 part B) evaluated the safety, pharmacokinetics, and neutralisation activity of a combination of three broadly neutralising monoclonal antibodies (PGDM1400LS, VRC07-523LS, and PGT121.414.LS) targeting diffe